Table 2.
Summary of the efficacy induced by the homologous and heterologous vaccination regimens.
| Challenge (2,000 spz) | Vaccine Regimen | Mouse Strain | Median Survival (Days) | Mean ± Standard Error (SEM) | Limits |
|---|---|---|---|---|---|
| Pb/PvVK210 | Naive | C57BL/6 | 4.89 | 4.84 ± 0.10 | 4.22–5.39 |
| Poly (I:C) | 5.03 | 5.10 ± 0.10*** | 4.73–5.92 | ||
| PPP (yPvCSP-AllCT) | 9.17 | 9.26 ± 0.16*** | 8.20–9.80 | ||
| PPP yPvCSP-AllFL) | 9.45 | 9.36 ± 0.14*** | 8.62–9.92 | ||
| Pb/PvVK247 | Naive | C57BL/6 | 4.48 | 4.66 ± 0.13 | 4.01–5.24 |
| Poly (I:C) | 4.92 | 4.96 ± 0.16*** | 4.25–5.82 | ||
| PPP (yPvCSP-AllCT) | 8.96 | 9.03 ± 0.12*** | 8.39–9.73 | ||
| PPP (yPvCSP-AllFL) | 8.94 | 9.03 ± 0.18*** | 8.16–10.64 | ||
| Pb/PvVK210 | Naive | BALB/c | 5.10 | 4.96 ± 0.12 | 4.07–5.56 |
| AdPP (AdHu5 + yPvCSP-AllCT) | 9.27 | 9.37 ± 0.14*** | 8.89–10.51 | ||
| AdPP (AdHu5 + yPvCSP-AllFL) | 9.48 | 9.55 ± 0.16*** | 8.88–10.52 | ||
| AdPP (AdC68 + yPvCSP-AllCT) | 9.20 | 9.53 ± 0.24*** | 8.92–11.90 | ||
| AdPP (AdC68 + yPvCSP-AllFL) | 9.12 | 9.44 ± 0.17*** | 8.78–10.63 | ||
| Pb/PvVK247 | Naive | BALB/c | 5.05 | 5.21 ± 0.13 | 4.67–5.97 |
| AdPP (AdHu5 + yPvCSP-AllCT) | 9.26 | 9.62 ± 0.21*** | 8.92–10.95 | ||
| AdPP (AdHu5 + yPvCSP-AllFL) | 9.52 | 9.68 ± 0.18*** | 8.99–10.73 | ||
| AdPP (AdC68 + yPvCSP-AllCT) | 9.54 | 9.73 ± 0.18*** | 9.08–10.27 | ||
| AdPP (AdC68 + yPvCSP-AllFL) | 9.17 | 9.63 ± 0.35*** | 8.72–12.37 |
Significant differences compared to naïve group are denoted on the table (***P < 0.001 in all cases, One way ANOVA).